SLRN חוב כולל להון ACELYRIN Inc.

Acelyrin, Inc. (SLRN) develops specialized treatments for severe inflammatory processes, including psoriasis, targeting patients at oncology centers. This historical price chart shows a total debt-to-equity ratio of 0.01. The firm's results depend on medical breakthroughs rather than macroeconomics. The company is currently scaling its innovative portfolio, focusing on final trials of drugs for the therapy of rare skin and eye diseases.

This ratio measures the degree of financial leverage by comparing total liabilities to net assets to assess the business's dependence on borrowed funds. For Acelyrin, Inc. (SLRN), whose success depends on clinical immunotherapy data, the debt-to-equity ratio history reflects the cost of capital during periods of volatility, determining the funding stability of research and development regardless of macroeconomic cycles.